SecBot SecBot

AXGN

Axogen, Inc.
Nasdaq· Electromedical & Electrotherapeutic Apparatus· Inc. MN· CIK 0000805928 Healthcare & Medical Devices
$55.38 −0.55 (−0.98%)
Nov 16 4:00 PM ET · prev $55.93
Market cap
$3.3B
Mid cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$60.00
+8% · range $56.00–65.00
1 year
+135.0%
from $23.57 · Nov 17
30 days
+57.2%
from $35.24
52-week range
$23.57–58.63
−6% from high · low Nov 17
Avg volume 20D
2.12M
Oct 28 spike 9.29M
Short interest
6.99M
≈11.7% of shares · +36.5%
Days to cover
3.3
at average volume
Insider net
−$6.5M
0 buyers · 9 sellers · since Feb 26
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
16
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 2 bearish · 7 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 10/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    9 insiders sold $6.5M.

  • InstitutionsMIXED

    Q3 2026: 23 added (1 new), 23 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +36.5% to 6.99M shares. 3.3 days to cover, ≈11.7% of shares.

  • TrendUPTREND

    28% above its 50-day average. New closing high $58.63 on Nov 11.

Who's buying

13F· Q3 2026
1
new positions
1
exit
FundMoveSharesValue
FMR LLCDOUBLED2,638,325$110.6M
MORGAN STANLEYTRIM1,790,100$75.0M
Artemis Investment Management LLPADD1,780,992$74.7M
DIMENSIONAL FUND ADVISORS LPADD539,087$22.6M
Assenagon Asset Management S.A.TRIM411,714$17.3M
Nuveen, LLCTRIM353,683$14.8M
Russell Investments Group, Ltd.DOUBLED334,902$14.0M
UBS Group AGTRIM281,131$11.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy5Buy11Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +8%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 29, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Oct 29, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 29, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Oct 29, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 29, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$6.5M
sold · 9 insiders
DateInsiderTypeValue
Sep 2, 2026
TYNDALL JOSEPH A.
Director
Sep 2, 2026
SELL$173.9K
Aug 11, 2026
Wendell Amy McBride
Director
Aug 11, 2026
EXERCISE$198.3K
Aug 11, 2026
Wendell Amy McBride
Director
Aug 11, 2026
SELL$646.6K
Aug 10, 2026
Began Marc A
EVP & General Counsel
Aug 10, 2026
EXERCISE$550.8K
Aug 10, 2026
Began Marc A
EVP & General Counsel
Aug 10, 2026
SELL$3.2M
Aug 7, 2026
Weiler Kathy Johnson
Director
Aug 7, 2026
SELL$641.0K
Jun 24, 2026
Burke William P. Mr.
Director
Jun 24, 2026
AWARD4,392 sh
Jun 24, 2026
JOHNSON JOHN
Director
Jun 24, 2026
AWARD4,392 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

12 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,991,930
shares short
+36.5%
vs prior settlement
3.3
days to cover
≈11.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

16 filings · 3 press releases · 6 bullish · 1 bearish · 4 mixed · 5 neutral
All AXGN filing & press-release reports (19)